A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation

American Journal of Clinical Pathology

Volumn 127, Issue 6, 2007, Pages 977-981

  Tan, Angela Y C ^a   Westerman, David A ^a,b   Dobrovic, Alexander ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chronic myeloproliferative disorders; JAK2; Method; Mutation detection; PCR; Polymerase chain reaction; V617F

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CELL MUTANT; CELL POPULATION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE; HUMAN; HUMAN CELL; JAK2 GENE; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; POSTPOLYCYTHEMIC MYELOFIBROSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THROMBOCYTHEMIA; GENETICS; METHODOLOGY; MIDDLE AGED; NUCLEOTIDE SEQUENCE;

JAK2 PROTEIN, HUMAN; JANUS KINASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 34250654512     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/1U61JVXTLPPQ7YP1     Document Type: Article

References (24)

1. Rane SG, Reddy EP. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19:5662-5679.
2. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
6. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
7. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
8. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
9. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105:4187-4190.
10. Tefferi A, Gilliland D. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80:947-958.
11. Greiner TC. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders [editorial]. Am J Clin Pathol. 2006;125:651-653.
12. Campbell PJ, Scott LM, Baxter EJ, et al. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders. In: Iland H, Hertzberg M, Marlton P, eds. Methods in Molecular Medicine: Myeloid Leukemia: Methods and Protocols. Vol 125. Totowa, NJ: Humana Press; 2006:253-264.
13. Bock O, Busche G, Koop C, et al. Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders. J Mol Diagn. 2006;8:170-177.
14. James C, Delhommeau F, Marzac C, et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia. 2006;20:350-353.
15. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125:625-633.
16. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
17. Sattler M, Walz C, Crowley BJ, et al. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples [letter]. Blood. 2006;107:1237-1238.
18. Tan A, Westerman D, McArthur GA, et al. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem. 2006;52:2250-2257.
19. Orou A, Fechner B, Utermann G, et al. Allele-specific competitive blocker PCR: a one-step method with applicability to pool screening. Hum Mutat. 1995;6:163-169.
20. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503-2516.
21. Nollau P, Wagener C. Methods for detection of point mutations: performance and quality assessment. The IFCC Scientific Division, Committee on Molecular Biology Techniques. J Int Fed Clin Chem. 1997;9:162-170.
22. Imyanitov EN, Buslov KG, Suspitsin EN, et al. Improved reliability of allele-specific PCR. Biotechniques. 2002;33:484, 486, 488, passim.
23. Lasho TL, Mesa R, Gilliland DG, et al. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol. 2005;130:797-799.
24. Stevenson WS, Hoyt R, Bell A, et al. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology. 2006;38:336-342.